Prostate Cancer, How I Stopped It's Progress and Reduced Its Size

Published: Sat, 12/09/23

Fenbendazole

The importance of microtubules in cell division, motility, intracellular trafficking, and their role in modulating cellular shape according to the environment has made them one of the most successful targets of anticancer therapy. Agents that perturb the microtubule dynamics have been widely used in cancer treatment. Considering the relative success of mitotic agents in the treatment of cancer, microtubules may be termed as one of the best cancer targets identified till now.

Microtubule targeting agents can be broadly classified into two major classes. The first class consists of microtubule-destabilizing agents, which inhibit microtubule polymerization. This class of anti-mitotic drugs includes several compounds such as the vinca alkaloids (vinblastine, vincristine, vinorelbine, vindesine, vinflunine), estramustine, colchicine and combretastatins, that are being used clinically or are under clinical investigation for cancer treatment. The second class is comprised of microtubule-stabilizing agents. These agents include paclitaxel, docetaxel, epothilones, and discodermolide. The consequence of disrupting tubulin and microtubule dynamics with both these classes of drugs in dividing cells is metaphase (cell division) arrest and induction of apoptosis (cell self-destruction).

Fenbendazole (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate) is a broad-spectrum benzimidazole anthelminthic (anti-parasitic) approved for use in numerous animal species. Repurposing of veterinary drugs showing promising results for human use can result in considerable time and cost reduction required to develop new drugs. Fenbendazole is known to have a high safety margin and most species tolerate it very well. It has very low degree of toxicity and high degree of safety in experimental animals. In this study, we show that fenbendazole (FZ) exhibits a moderate micro-tubule de-polymerizing activity towards human cancer cells but possesses a potent anti-tumor effect as evident from in vitro and in vivo experiments. Our results indicate that FZ exerts its antitumor effect through the disruption of microtubule dynamics, p53 activation and the modulation of genes involved in multiple cellular pathways. FZ treatment also resulted in reduced glucose uptake in cancer cells due to down regulation of GLUT transporters and key glycolytic enzymes.[1]

My prostate cancer continued to persist over the years. I’ve used PNC-27, Foxo4-DIR, Two Feathers and Ozone Rectally to cause the cancer and enlargement of my prostate to regress. However, once I started to use Fenbendazole at a rate of 444mg 2x per day, is when I started to notice a regression of my prostate size and a return of more ease of urine flow.

Therefore, I now recommend for the eradication of all cancers in the body to take Fenbendazole Power at the rate of use either 222mg or 444 mg 2-3x per day with. Because Fenbendazole has an irritating effect on the digestive tract, dosage can vary according to what you tolerate from 222mg to 444 mg 2-3x per day. I recommend taking this at the end of your meals. This causes it to mix with the food in your stomach and is therefore less irritating to your intestines.

[1] https://www.nature.com/articles/s41598-018-30158-6

Fenbendazole

Drugs that are already clinically approved or experimentally tested for conditions other than cancer, but are found to possess previously unrecognized cytotoxicity towards malignant cells, may serve as fitting anti-cancer candidates. Methyl N-(6-phenylsulfanyl-1H benzimidazol-2-yl) carbamate [Fenbendazole, FZ], a benzimidazole compound, is a safe and inexpensive anthelmintic drug possessing an efficient anti-proliferative activity. In our earlier work, we reported a potent growth-inhibitory activity of FZ caused partially by impairment of proteasomal function. Here, we show that FZ demonstrates moderate affinity for mammalian tubulin and exerts cytotoxicity to human cancer cells at micromolar concentrations. Simultaneously, it caused mitochondrial translocation of p53 and effectively inhibited glucose uptake, expression of GLUT transporters as well as hexokinase (HK II) - a key glycolytic enzyme that most cancer cells thrive on. It blocked the growth of human xenografts in nu/nu mice model when mice were fed with the drug orally. The results, in conjunction with our earlier data, suggest that FZ is a new microtubule interfering agent that displays anti-neoplastic activity and may be evaluated as a potential therapeutic agent because of its effect on multiple cellular pathways leading to effective elimination of cancer cells.

$125.00

Buy Now!

PNC-27

PNC-27 is a synthetically created peptide designed to specifically target and destroy cancer cells. It is a member of the PNC set of investigational proteins designed to attach to malformed (cancerous) cells and cause them to die through cell necrosis, all while leaving normal, healthy cells intact and unharmed.

The PNC-27 peptide contains an HDM-2 binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain. This has been found to enable the peptide to bind to and kill cancer cells through membranolysis, or disruption of the cell membrane.

Through research and study on animal subjects, the PNC-27 peptide has been shown to be highly effective in selectively targeting a wide variety of specific forms of cancer, including pancreatic cancer, breast cancer, leukemia, melanoma, and additional cancer lines.

$375.00 - 10 vials (can take 3 to 4 weeks to get if out of stock)

Buy Now!

Stephen Heuer, B.S. Nutripath

May You Have The Life Force To Life In Joy

stephen@sygn44.com

stephen@sygn44.com

160 Dewey Rd.
Greer SC 29651
USA

Unsubscribe | Change Subscriber Options